OncoCyte Corporation to Present at the 2016 Aegis Growth Conference
September 20 2016 - 6:30AM
OncoCyte Corporation (NYSE MKT:OCX), a developer of novel,
non-invasive tests for the early detection of cancer, today
announced that William Annett, Chief Executive Officer, is
scheduled to present an overview of the Company and its progress at
the 2016 Aegis Growth Conference on Thursday, September 22, 2016 at
5:30 p.m. ET/ 2:30 p.m. PT. The conference will be held
at the Encore at Wynn Hotel in Las Vegas.
A live webcast and subsequent archived replay of
the Company’s presentation may be accessed via the investor
relations section of the Company’s website.
About OncoCyte Corporation
OncoCyte is primarily focused on the development
and commercialization of novel, non-invasive blood and urine
(“liquid biopsy”) diagnostic tests for the early detection of
cancer to improve health outcomes through earlier diagnoses, to
reduce the cost of care through the avoidance of more costly
diagnostic procedures, including invasive biopsy and cystoscopic
procedures, and to improve the quality of life for cancer patients.
While current biopsy tests use invasive surgical procedures to
provide tissue samples in order to determine if a tumor is benign
or malignant, OncoCyte is developing a next generation of
diagnostic tests that will be based on liquid biopsies using blood
or urine samples. OncoCyte’s pipeline products are intended to be
confirmatory diagnostics for detecting lung, bladder and breast
cancer. OncoCyte’s diagnostic tests are being developed using
proprietary sets of genetic and protein markers that differentially
express in specific types of cancer.
Investor Contact:
EVC Group, Inc.
Michael Polyviou/Amanda Prior
646-445-4800
mpolyviou@evcgroup.com /aprior@evcgroup.com